Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

NCT02446093 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

54

Enrollment

INDUSTRY

Sponsor class

Conditions

Borderline Resectable Pancreatic Adenocarcinoma

Interventions

BIOLOGICAL: Aglatimagene besadenovec
RADIATION: Chemoradiation
RADIATION: Stereotactic body radiation therapy
PROCEDURE: Surgery

Sponsor

Candel Therapeutics, Inc.

Collaborators

[object Object]